Indian Globalization Capital Inc. (NASDAQ: IGC) stock gained by 4.07% at last close while the IGC stock price surged further by 3.91% in the after-hours trading. India Globalization Capital is involved in the research and making of cannabinoid-based treatments for medical use. Presently, the corporation has two business units: life sciences and infrastructure.
IGC stock’ Current Development
India Globalization Capital has released preliminary findings for its Phase 1 IGC-AD1 clinical trial’s exploratory endpoints. IGC-AD1 is an unique marijuana-based investigational novel medication candidate for Alzheimer’s disease patients. The Phase 1 clinical trial yielded valuable information on pharmacokinetics (PK) and genotyping, which will be crucial in understanding optimal dosing in subsequent trials, pending FDA approval.
On December 1, 2021, the clinical study outcomes were posted to the FDA in the form of a Clinical/Statistical Report (“CSR”). Furthermore, data from the secondary endpoints, neuropsychiatric symptoms in Alzheimer’s patients, and other pertinent data are available on a Form 8-K filed with the Securities and Exchange Commission on December 2, 2021, as previously stated.
Nearly 50 million people around the globe are affected by Alzheimer’s disease, with women accounting for roughly 66 percent of those affected (alz.org). Sadly, there is no treatment for Alzheimer’s disease, and there are no FDA-approved medications to treat many of the signs and symptoms, particularly agitation.
About Pharmacokinetics,
Pharmacokinetics is the study of how long it takes for a drug to be absorbed, processed, metabolised, and eliminated by the body after it has been given. Considering how much time a medicine will take to yield the required effects and when those effects fade can aid in determining the most appropriate and safe dose frequency.
Final results obtained show that,
Pharmacokinetics data suggest that administering two or three times per day may be appropriate for patients because the first and perhaps second doses would be removed from the body before future doses.
However, pending FDA permission, the genotyping findings will be used to guide the design of Phase 2 and Phase 3 clinical trials. IGC-AD1 is an experimental novel medicine that has not been approved by any regulatory agency in any nation as a treatment. Despite the fact that the Phase 1 trial was completed and some data was obtained, IGC-safety, AD1’s tolerability, and efficacy must be confirmed in bigger and more disparate groups of Alzheimer’s patients.
